Medical oncology
-
Multicenter Study
HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.
This study mainly focused on the impact of Hepatitis B virus (HBV) infection on the prognosis of diffuse large B cell lymphoma (DLBCL) patients in rituximab era, using a Cox regression model to ascertain the prediction value of the serum HBV marker in survivals. Three hundred and eighty four DLBCL patients treated with rituximab, cyclophosphamide, doxorubicin/epirubicin, vincristine and prednisone (R-CHOP-like regimens) or CHOP-like regimens were included. ⋯ In the CHOP group, HBV infection has not been found a profound impact on the survivals. In the R-CHOP group, PFS and OS were inferior in HBsAg-positive patients (p=0.031 and p=0.006, respectively); after adjusting for International Prognostic Index parameters, HBsAg is an independent unfavorable factor for both PFS (RR=2.492) and OS (RR=2.589).
-
Critical care for advanced lung cancer patients is still controversial, and the appropriate method for the selection of patients who may benefit from intensive care unit (ICU) care is not clearly defined. We retrospectively reviewed the medical records of stage IIIB-IV lung cancer patients admitted to the medical ICU of a university hospital in Korea between 2003 and 2011. Of 95 patients, 64 (67%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS)≥2, and 79 (84%) had non-small-cell lung cancer. ⋯ Certain advanced lung cancer patients may benefit from ICU management. However, refractory patients and patients with a poor PS do not seem to benefit from ICU care. Oncologists should try to discuss palliative care and end-of-life issues in advance to avoid futile care.
-
Comparative Study
NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma.
The aim of this study was to investigate neural precursor cell expressed developmentally down-regulated 9 (NEDD9) expression in human gastric carcinoma (GC) and to explore its clinic significance. NEDD9 expression was detected by immunohistochemistry in GC, their corresponding paracancerous histological normal tissues (PCHNTs), and gastric normal tissues. And this result was further confirmed at the protein and mRNA level by Western blotting and quantitative real-time PCR, respectively. ⋯ And we also detected frequently NEDD9 up-regulation in both protein and mRNA levels in GC tissues as compared to PCHNTs. Kaplan-Meier survival analysis showed that high NEDD9 expression exhibited a significant correlation with poor prognosis for gastric cancer patients. Our data suggested that NEDD9 could be used as prognostic molecular marker to be applied in the clinical setting to diagnosis, evaluating patient's outcome (prognosis and recurrence) for GC patients.
-
The proximal malignant obstructive jaundice remains one of the most challenging problems for hepato-biliary surgeons. Particularly when the findings preclude surgical resection at exploration, the next decision seems hard to make. A novel palliative treatment called "hepato-biliary-enteric stent drainage" was designed for these proximal malignant obstructive jaundice patients. ⋯ No procedure-related bleeding, bile leakage, pancreatitis were observed. The median survival time was 212 days, half-year and 1-year survival rate were 56.5 and 21.7%, respectively. Hepato-biliary-enteric stent drainage with less expense, less complications, and easy operation may be an ideal option for patients with unresectable malignancy in the hilar region at exploration.